FANGSHIZHEN CAPITAL
FANGSHIZHEN CAPITAL
Status:
Active
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-22 | MAXVAX | Fangshizhen Capital investment in Series B - MAXVAX | 500 M CNY |
More informations about "Fangshizhen Capital"
关于我们 - 红杉中国 - HongShan
红杉中国是专注于投资科技、医疗健康、消费三大领域的私募股权投资机构。 自2005年成立以来，红杉中国致力于发掘和培育创新和创业力量，在海内外投资了逾1500家企业，其中涌现出许多具有鲜明技术特征、创新商业模式、具备高成 …See details»
Chinese Biotechs Garner Millions for Shingles Vaccine ... - BioSpace
Jul 22, 2022 Vaccines developer Maxvax raised nearly CNY500 million (approx. $74 million) from a Series B funding round led by China Life Private Equity Investment, with support from …See details»
Our team - Hillhouse Investment
Collectively from over 18 countries, our international team comprises of over 50 investment professionals who contribute a wealth of experience, industry knowledge, and a shared commitment to excellence.See details»
Vaccines Developer Maxvax Closes a Nearly CNY 500 Million …
Jul 21, 2022 Fangshizhen Capital and Xinshang Capital, two new investors, also participated in this round. Maxvax plans to use the funds to conduct clinical trials of multiple vaccine …See details»
Fangshizhen Capital — 1 Investments, Exits, 1 Portfolio companies ...
Fangshizhen Capital. Search. Overview Investments Unlock datapoints. Portfolio analytics Team News & Media. Add fund to favorites. Save this fund for later to form your own custom list of …See details»
Team - C Capital
Chief Executive Officer of C Capital. Clive Ng. Co-founder of C Capital PE (US) Private Equity. Simon Shi. Managing Director and Head of China PE. Suzie Qiu. Managing Director. Zhen …See details»
Mr. ZHANG Zheng - fshl.com
Aged 38, was appointed on 1 April 2021 as an ED. Mr. ZHANG graduated with a Bachelor Degree in Economics from Renmin University of China University in 2009, and a Master’s Degree in …See details»
Fangshizhen Capital - Investments, Portfolio & Company Exits
Fangshizhen Capital is a venture capital investment firm.See details»
Fangshizhen Capital - Updates, News, Events, Signals & Triggers
Fangshizhen Capital is a venture capital investment firm.See details»
K193 bispecific antibody(Beijing Lüzhu Biotechnology)
Mar 20, 2025 Originator Organization. Beijing Lüzhu Biotechnology Co., Ltd. Active Organization. Beijing Lüzhu Biotechnology Co., Ltd. Inactive Organization-Drug Highest Phase …See details»
Chinese Biotechs Garner Millions for Shingles Vaccine Candidate …
Jul 22, 2022 Vaccines developer Maxvax raised nearly CNY500 million (approx. $74 million) from a Series B funding round led by China Life Private Equity Investment, with support from …See details»
方正中期 - founderfu
Founder Cifco futures always keeps in mind the responsibility and mission of serving the real economy and national strategy, gives full play to the advantages and expertise of the futures …See details»
Beijing Lüzhu Biotechnology Co., Ltd. - Drug pipelines, Patents ...
Mar 8, 2025 Maxvax Raises $74 Million To Expand Chinese Operations Vaccines developer Maxvax raised nearly CNY500 million (approx. $74 million) from a Series B funding round led …See details»
Shenzhen Fanshi Capital Management Co., Ltd. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Shenzhen Fanshi Capital Management Co., Ltd. of Shenzhen, Guangdong. Get the latest business …See details»
OCGFC - Shahid Bolsen
The Owners and Controllers of Global Financialized Capital The OCGFC do not have an ideology, or anyway, ideology does not guide their decisions. However, states and populations do have …See details»
MAXVAX - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Bob Xu Steps Back, Anna Fang Steps Forward: China's First
Oct 16, 2023 This angel investment organization, founded by Xu Xiaoping and Wang Qiang in 2011, has managed seven funds with an AUM (assets under management) of over 12 billion …See details»
Beijing Lüzhu Biotechnology Co., Ltd. - synapse.zhihuiya.com
Mar 8, 2025 Maxvax Raises $74 Million To Expand Chinese Operations Vaccines developer Maxvax raised nearly CNY500 million (approx. $74 million) from a Series B funding round led …See details»
Dai Zhen - Stanford Encyclopedia of Philosophy
3 days ago They are simply the appropriate order or pattern of organization of the concrete, everyday world, which can be discovered through detailed investigation based on evidence. ...See details»
Fangshizhen Capital - Crunchbase
Fangshizhen Capital is a venture capital investment firm.See details»